Nightstar治療 NITE 深 滬
已收盤 12-12 16:00:00 美东时间
37.0868
-0.112
-0.30%
華盛通- 最 高37.0868
- 今 開37.1992
- 成交量 174股
- 最 低 37.0868
- 昨 收 37.1992
- 總市值 3054.84万
- 52周最高 37.1992
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 22.38
- 委 比 0.00%
- 總股本 82.37万
- 歷史最高 37.1992
- 量 比 0.25
- 振 幅 0.00%
- 歷史最低 10.99
- 每 手 1
- 風險率 3.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SPS Commerce to Present at the Nasdaq 53rd Investor Conference
SPS Commerce Inc. announces that its management will present at the Nasdaq 53rd Investor Conference on December 9, 2025, at 3:00 PM GMT. A webcast will be available on its investor relations website. SPS is a global leader in retail supply chain cloud services, serving over 50,000 customers and achieving 99 consecutive quarters of revenue growth.
12-02 21:16
CHIPOTLE REUNITES HOMETOWN FRIENDS WITH A BUY-ONE-GET-ONE (BOGO) ENTRÉE OFFER ON THANKSGIVING EVE
On the night before Thanksgiving, a popular time for young adults to reconnect with friends, Chipotle will fuel hometown reunions with an in-restaurant BUY-ONE-GET-ONE (BOGO) entrée offer on...
11-20 20:53
Varonis Announces New Microsoft Purview DSPM Integration
Varonis and Microsoft Purview have integrated their systems to enhance data security and visibility for organizations. This collaboration allows data security teams to monitor sensitive data across platforms like Salesforce and Microsoft 365, addressing risks associated with AI adoption. The integration simplifies security operations, reduces blind spots, and streamlines risk management. Customers can access data asset and risk information throug...
11-18 20:00
MACOM to Manufacture HRL’s 40nm GaN-on-SiC Process
MACOM Technology Solutions Inc. and HRL Laboratories have entered into an agreement for MACOM to exclusively license and manufacture HRL’s proprietary 40nm T3L GaN-on-silicon carbide process technology. The T3L process, developed under U.S. defense programs, offers advanced performance at millimeter-wave frequencies and is ideal for commercial and defense applications. MACOM will transfer the technology to its U.S. Trusted Foundries and integrate...
11-04 13:30
Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis
Amgen and Kyowa Kirin report positive interim results for rocatinlimab, showing long-term safety and sustained efficacy in moderate to severe atopic dermatitis patients.
09-10 03:06
Amgen, Kyowa Kirin announce long-term Phase 3 data for eczema drug
Amgen (NASDAQ:AMGN) and Kyowa Kirin (OTCPK:KYKOF) announced on Tuesday that their antibody therapy rocatinlimab is safe and effective in the long term, based on data from a Phase 3 trial for patients ...
09-09 19:08
III期临床赢了，股价却暴跌？赛诺菲OX40的魔幻时刻
（来源：求实药社） 又一项针对自免炎症的单抗三期临床成功了。赛诺菲今日宣布消息，其靶向OX40L（OX40配体）的全人源非T细胞耗竭性单克隆抗体——Amlit...
09-05 11:46
Trump Set To Appear At Ryder Cup's First Day In New York, Says Keegan Bradley Should 'Definitely' Be On The Team
Trump to attend opening round of Ryder Cup, endorses Bradley as U.S. captain. Event in Sept. at Bethpage Black, first time in New York.
08-25 15:27
ClearPoint Neuro Achieves Key Milestones With First U.S. Commercial Gene Therapy Infusions Using SmartFlow Device For AADC Deficiency
ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced multiple key milestones demonstrating the
08-05 04:37
Clorox Reports Q4 and FY25 Results, Provides FY26 Outlook
Delivers strong margin expansion and adjusted EPS growth for FY25 despite challenging environment in the second half of the fiscal year OAKLAND, Calif., July 31, 2025 /PRNewswire/ -- The Clo...
08-01 04:10
